About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Anti-inflammatory Drugs Market Size, Demand & Growth | By 2031
Anti-inflammatory Drugs Market

Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Drug Class (Steroids, NSAIDs, Biologics and Biosimilars, Other Drug Classes), By Applications (Autoimmune Diseases, Respiratory Diseases, Other Diseases), By Route of Administration (Parenteral, Oral, Topical, Inhalation) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI55182DR
Author : Straits Research
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Anti-inflammatory Drugs Market Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Steroids
        1. By Value
      3. NSAIDs
        1. By Value
      4. Biologics and Biosimilars
        1. By Value
      5. Other Drug Classes
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Autoimmune Diseases
        1. By Value
      3. Respiratory Diseases
        1. By Value
      4. Other Diseases
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Parenteral
        1. By Value
      3. Oral
        1. By Value
      4. Topical
        1. By Value
      5. Inhalation
        1. By Value
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Steroids
        1. By Value
      3. NSAIDs
        1. By Value
      4. Biologics and Biosimilars
        1. By Value
      5. Other Drug Classes
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Autoimmune Diseases
        1. By Value
      3. Respiratory Diseases
        1. By Value
      4. Other Diseases
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Parenteral
        1. By Value
      3. Oral
        1. By Value
      4. Topical
        1. By Value
      5. Inhalation
        1. By Value
    5. U.S.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Steroids
          1. By Value
        3. NSAIDs
          1. By Value
        4. Biologics and Biosimilars
          1. By Value
        5. Other Drug Classes
          1. By Value
      2. By Applications
        1. Introduction
          1. Applications By Value
        2. Autoimmune Diseases
          1. By Value
        3. Respiratory Diseases
          1. By Value
        4. Other Diseases
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Parenteral
          1. By Value
        3. Oral
          1. By Value
        4. Topical
          1. By Value
        5. Inhalation
          1. By Value
    6. Canada
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Steroids
        1. By Value
      3. NSAIDs
        1. By Value
      4. Biologics and Biosimilars
        1. By Value
      5. Other Drug Classes
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Autoimmune Diseases
        1. By Value
      3. Respiratory Diseases
        1. By Value
      4. Other Diseases
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Parenteral
        1. By Value
      3. Oral
        1. By Value
      4. Topical
        1. By Value
      5. Inhalation
        1. By Value
    5. U.K.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Steroids
          1. By Value
        3. NSAIDs
          1. By Value
        4. Biologics and Biosimilars
          1. By Value
        5. Other Drug Classes
          1. By Value
      2. By Applications
        1. Introduction
          1. Applications By Value
        2. Autoimmune Diseases
          1. By Value
        3. Respiratory Diseases
          1. By Value
        4. Other Diseases
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Parenteral
          1. By Value
        3. Oral
          1. By Value
        4. Topical
          1. By Value
        5. Inhalation
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Steroids
        1. By Value
      3. NSAIDs
        1. By Value
      4. Biologics and Biosimilars
        1. By Value
      5. Other Drug Classes
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Autoimmune Diseases
        1. By Value
      3. Respiratory Diseases
        1. By Value
      4. Other Diseases
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Parenteral
        1. By Value
      3. Oral
        1. By Value
      4. Topical
        1. By Value
      5. Inhalation
        1. By Value
    5. China
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Steroids
          1. By Value
        3. NSAIDs
          1. By Value
        4. Biologics and Biosimilars
          1. By Value
        5. Other Drug Classes
          1. By Value
      2. By Applications
        1. Introduction
          1. Applications By Value
        2. Autoimmune Diseases
          1. By Value
        3. Respiratory Diseases
          1. By Value
        4. Other Diseases
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Parenteral
          1. By Value
        3. Oral
          1. By Value
        4. Topical
          1. By Value
        5. Inhalation
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Singapore
    11. Taiwan
    12. South East Asia
    13. Rest of Asia-Pacific
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Steroids
        1. By Value
      3. NSAIDs
        1. By Value
      4. Biologics and Biosimilars
        1. By Value
      5. Other Drug Classes
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Autoimmune Diseases
        1. By Value
      3. Respiratory Diseases
        1. By Value
      4. Other Diseases
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Parenteral
        1. By Value
      3. Oral
        1. By Value
      4. Topical
        1. By Value
      5. Inhalation
        1. By Value
    5. UAE
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Steroids
          1. By Value
        3. NSAIDs
          1. By Value
        4. Biologics and Biosimilars
          1. By Value
        5. Other Drug Classes
          1. By Value
      2. By Applications
        1. Introduction
          1. Applications By Value
        2. Autoimmune Diseases
          1. By Value
        3. Respiratory Diseases
          1. By Value
        4. Other Diseases
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Parenteral
          1. By Value
        3. Oral
          1. By Value
        4. Topical
          1. By Value
        5. Inhalation
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Steroids
        1. By Value
      3. NSAIDs
        1. By Value
      4. Biologics and Biosimilars
        1. By Value
      5. Other Drug Classes
        1. By Value
    3. By Applications
      1. Introduction
        1. Applications By Value
      2. Autoimmune Diseases
        1. By Value
      3. Respiratory Diseases
        1. By Value
      4. Other Diseases
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Parenteral
        1. By Value
      3. Oral
        1. By Value
      4. Topical
        1. By Value
      5. Inhalation
        1. By Value
    5. Brazil
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Steroids
          1. By Value
        3. NSAIDs
          1. By Value
        4. Biologics and Biosimilars
          1. By Value
        5. Other Drug Classes
          1. By Value
      2. By Applications
        1. Introduction
          1. Applications By Value
        2. Autoimmune Diseases
          1. By Value
        3. Respiratory Diseases
          1. By Value
        4. Other Diseases
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Parenteral
          1. By Value
        3. Oral
          1. By Value
        4. Topical
          1. By Value
        5. Inhalation
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Anti-inflammatory Drugs Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Merck
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Pfizer
    3. Novartis
    4. GSK
    5. Johnson & Johnson
    6. AbbVie
    7. Eli Lilly
    8. Bristol Myers Squibb
    9. Bristol-Myers Squibb Company
    10. UCB
    11. Mylan
    12. Aurobindo Pharma
    13. Sun Pharmaceutical Industries
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Anti-Inflammatory Therapeutics Market Size The global anti-inflammatory therapeutics market size was valued at USD 111.78 billion in 2024 and is projected to grow from USD 115.25 billion in 2025 to reach USD 152.78 million b
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.